Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted
Thesis Summary

Macerich is successfully transitioning from a turnaround story to a core earnings growth phase under its 'Path Forward Plan'. By aggressively recycling capital, walking away from underperforming assets (such as the Santa Monica Place default), and focusing on its high-productivity Class A regional malls, the company is driving a powerful earnings ramp projected for 2027/2028. Operational momentum is highly visible, highlighted by a robust Signed Not Open (SNO) leasing pipeline of $116 million that is expected to scale to $140 million. Deleveraging progress is also ahead of schedule, with net debt to EBITDA reduced from 8.76x at year-end 2023 to 7.76x as of Q1 2026, targeting 6.0x. Recent tactical acquisitions, like the Annapolis Mall, further demonstrate management's ability to execute accretive transactions using improved equity valuations.

Sign in / Sign up to read more
This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.
Street view · analyst 12-month targets16 analysts · as of 18 Aug 2026
Low · most bearish analyst$19.00
Mean target$26.63
High · most bullish analyst$30.00
Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.
Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026
Scenarios · 12-month scenario targetsAnchored at research date
Bear CaseDownside scenario
$19.00

Macroeconomic headwinds or a consumer spending slowdown cause elevated tenant bankruptcies, offsetting new store openings and keeping occupancy flat in the low-90s. Asset sales stall due to tight credit markets, leaving leverage elevated above 7.5x. FFO per share fails to ramp, landing at or below $1.70 by 2028.

Base CaseCentral scenario
$26.63
Matches the consensus mean

Macerich executes steadily on its Path Forward Plan, completing $600M to $700M of planned dispositions and givebacks through 2027. Go-Forward Portfolio NOI grows at a 3% to 4% CAGR, and the SNO pipeline steadily commences operations. Leverage declines gradually toward 6.5x, and FFO per share reaches the midpoint of the 2028 target ($1.90).

Bull CaseUpside scenario
$30.00

The SNO pipeline converts to active leases faster than expected, driving Go-Forward Portfolio NOI growth above 5% annually. Dispositions of non-core assets execute at highly favorable cap rates, accelerating deleveraging to the 6.0x net debt to EBITDA target by late 2027. Strong retail demand allows double-digit leasing spreads, pushing 2028 FFO per share to the top of the guided range ($2.00).

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits
  • High-quality Class A regional mall portfolio generating robust sales of $941 per square foot.
  • Highly visible, contracted growth from a $116 million Signed Not Open (SNO) leasing pipeline.
  • Successful execution of the Path Forward Plan, resulting in a 1.5x reduction in leverage since 2023.
  • Accretive capital allocation, as demonstrated by the strategic acquisition of Annapolis Mall.
Sign in / Sign up to read more
Key Investment Risks
  • Elevated leverage relative to higher-rated retail REIT peers.
  • Sensitivity to consumer discretionary spending and macroeconomic downturns.
  • Execution risk associated with completing $600M to $700M of remaining non-core asset dispositions.
Sign in / Sign up to read more

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Explore this dossier

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.